N-Oleoyl glycine

Research use only, not for human use.

N-Oleoyl glycine, a lipoamino acid, was able to promote 3T3-L1 adipogenesis through the activation of CB1 receptor and the enhancement of insulin-mediated Akt signaling pathway.

N-Oleoyl glycine, a lipoamino acid, was able to promote 3T3-L1 adipogenesis through the activation of CB1 receptor and the enhancement of insulin-mediated Akt signaling pathway.(In Vitro):N-Oleoyl glycine stimulated lipid accumulation and significantly increased adipogenic genes (PPARγ and aP2), in a dose- and time-dependent manner. Additionally, N-Oleoyl glycine markedly increased the mRNA expression of CB1 receptor and the inhibition of CB1R by its antagonist SR141716 abolished the promotive effects of N-Oleoyl glycine on lipid accumulation and the protein expression of PPARγ and aP2. Furthermore, N-Oleoyl glycine increased the ratio of p-Akt/Akt and p-FoxO1/FoxO1, which could be reversed by SR141716. Moreover, N-Oleoyl glycine-induced enhancement of adipogenesis, activation of insulin-mediated Akt signaling pathway and inactivation of FoxO1 were effectively blocked by Wortmannin, a specific PI3K/Akt inhibitor, indicating the essential role of Akt signaling pathway in the process of N-Oleoyl glycine-stimulated 3T3-L1 adipogenesis.

N-Oleoyl glycine is a lipoamino acid, which stimulates adipogenesis associated with activation of CB1 receptor and Akt signaling pathway in 3T3-L1 adipocyte. N-Oleoyl glycine (1, 5, 10, 20, 50 μM) dose- and time-dependently stimulates 3T3-L1 adipogenesis after treatment for 1-10 days via activation of CB1R. N-Oleoyl glycine also elevates Akt signaling pathway during the differentiation of 3T3-L1 adipocytes.

——

——

GPCR/G Protein

Cannabinoid Receptor

CYP3A

——

——

2601-90-3

339.52

C20H37NO3

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (294.54 mM)

CCCCCCCC\C=C/CCCCCCCC(=O)NCC(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years